Although researchers are in agreement that upregulated VEGF-D in response to antiangiogenic drugs might be one of the key factors enabling antiangiogenic drug resistance in cancers [103], little is known about the signaling pathways and expression regulators involved. The gene discussed is VEGFD; the disease is cancer.